While much of the funding to the ‘dark money’ behemoths tied to the leaders of Congress remains a mystery, a review of corporate disclosures reveals more of the companies that have donated.
Donald Shaw
Donald Shaw is a money-in-politics reporter and a co-founder of Sludge.
Gallego Opposes Progressives on Cutting Pentagon Budget
In repeated votes, Gallego has sided against amendments from his Progressive Caucus colleagues that would have reduced the Department of Defense budget by 10 percent.
How Manchin Capitalized on Being at the Center of the IRA Debate
The senator formed a new fundraising vehicle that lets him solicit larger contribution checks.
Corporate America Is Helping to Elect Anti-Abortion Attorneys General
Abortion access is on the ballot in several states this year, where Democratic AG candidates have pledged not to enforce restrictive abortion laws and Republicans have said the opposite.
Three More Senators Violated the STOCK Act
At least two more Democrats and a Republican senator failed to report stock transactions last year as a ban on congressional stock trading flounders in a Senate working group.
Supreme Court Strikes Candidate Loan Repayment Limits
A case brought by Sen. Ted Cruz now means candidates who loan their campaigns more than $250,000 can repay themselves with contributions raised after they are elected.
Fossil Fuel Allies in Congress Stand With Embattled Rep. Henry Cuellar
Cuellar, who has the worst environmental voting record of any Democrat in Congress, faces a competitive primary challenge from Green New Deal backer Jessica Cisneros.
Another Possible Stock Trading Loophole
Members of Congress would be allowed to continue trading industry funds under the two leading stock trading ban bills in Congress.
Major U.S. Companies Slam Voter Suppression Laws, Then Donate to Their Sponsors
The companies’ donations appear to contradict their public statements in support of voting rights.
Biden’s Pick for FDA Could Squeak Through With Help From Pharma-Funded Republicans
Four Republicans with extensive ties to the pharmaceutical industry plan to support Robert Califf’s Senate confirmation.

